RECOMBINANT HUMAN FACTOR VIIA (RFVIIA) IN A RABBIT STASIS MODEL

被引:38
|
作者
DINESS, V
BREGENGAARD, C
ERHARDTSEN, E
HEDNER, U
机构
[1] Novo Nordisk A/S, DK-2880 Bagsvaerd, Novo Alle
关键词
FVIIA; DIC; RABBIT STASIS MODEL;
D O I
10.1016/0049-3848(92)90142-W
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The thrombogenicity of recombinant human FVIIa (rFVIIa) and FEIBA was studied in a rabbit stasis model. Only minor thrombus formation in isolated vein segments during 10 min. of stasis was seen following the administration of rFVIIa 100-1000-mu-g/kg or FEIBA 50-100 U/kg whereas both compounds caused clear thrombus formation during 30 min. of stasis. RFVIIa caused no change in platelet counts or plasma fibrinogen 3 hours after administration, whereas a small decrease of APTT was seen due to the direct effect of rFVIIa in this assay. In contrast, FEIBA caused a significant and dose-dependent decrease of platelet counts as well as of fibrinogen, and an increase of APTT which demonstrate a general consumption of coagulation factors. In conclusion the study demonstrated a local pharmacological effect of rFVIIa in the absence of a general activation of the coagulation cascade.
引用
收藏
页码:233 / 241
页数:9
相关论文
共 50 条
  • [1] RECOMBINANT HUMAN FACTOR-VIIA IN A RABBIT STASIS MODEL
    DINESS, V
    BREGENGARD, C
    HEDNER, U
    [J]. THROMBOSIS AND HAEMOSTASIS, 1991, 65 (06) : 1159 - 1159
  • [2] Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets
    Gabriel, DA
    Li, X
    Monroe, DM
    Roberts, HR
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (10) : 1816 - 1822
  • [3] Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date
    Giansily-Blaizot, Muriel
    Schved, Jean-Francois
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2017, 8 (12) : 345 - 352
  • [4] CHANGING USE OF RECOMBINANT :FACTOR VIIA (RFVIIA) FOR UNCONTROLLABLE HAEMORRHAGE
    Pugh, R.
    Wenstone, R.
    [J]. INTENSIVE CARE MEDICINE, 2011, 37 : S151 - S151
  • [5] Recombinant activated factor VIIA (RFVIIA)use in children.
    Alten, Jeffrey A.
    Benner, Kim W.
    Green, Kelsey
    [J]. CRITICAL CARE MEDICINE, 2007, 35 (12) : A201 - A201
  • [6] The use of recombinant factor VIIa (rFVIIa) in advanced liver disease
    Bernstein, DE
    Jeffers, LJ
    Erhardtsen, E
    Reddy, KR
    Bech, RM
    Hedner, U
    Schiff, ER
    [J]. THROMBOSIS AND HAEMOSTASIS, 1997, : PS343 - PS343
  • [7] Immunological aspects of recombinant factor VIIa (rFVIIa) in clinical use
    Nicolaisen, EM
    Hansen, LL
    Poulsen, F
    Glazer, S
    Hedner, U
    [J]. THROMBOSIS AND HAEMOSTASIS, 1996, 76 (02) : 200 - 204
  • [8] Thrombogenicity of recombinant factor VIIa and recombinant soluble tissue factor in an in vivo rabbit model
    Turecek, PL
    Richter, G
    Muchitsch, EM
    Pichler, L
    Schwarz, HP
    [J]. THROMBOSIS AND HAEMOSTASIS, 1997, : PS903 - PS903
  • [9] Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
    Gopalakrishnan, R.
    Hedner, U.
    Ghosh, S.
    Nayak, R. C.
    Allen, T. C.
    Pendurthi, U. R.
    Rao, L. V. M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (02) : 301 - 310
  • [10] Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent
    Ulla Hedner
    Nikolai C. Brun
    [J]. Neuroradiology, 2007, 49 : 789 - 793